Effect of chronic hypoxia on RAGE and its soluble forms in lungs and plasma of mice

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 5, 2015, Pages 992-1000

  Gopal, P ^a   Gosker, H R ^a   De Theije, C C ^a   Eurlings, I M ^a   Sell, D R ^b   Monnier, V M ^b   Reynaert, N L ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AGEs; Detoxification; Hypoxia; RAGE expression; Shedding

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; HIGH MOBILITY GROUP B1 PROTEIN; HYPOXIA INDUCIBLE FACTOR; MESSENGER RNA; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; ADAM PROTEIN; ADAM10 PROTEIN, MOUSE; ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCOSYLATION END-PRODUCT RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN RECEPTOR; ISOPROTEIN; LACTOYLGLUTATHIONE LYASE; MEMBRANE PROTEIN; SECRETASE;

A549 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PH; CHRONIC DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE COUNT; GENE EXPRESSION; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HOMEOSTASIS; HYPOXIA; IN VITRO STUDY; LONG TERM EXPOSURE; LUNG; LUNG PARENCHYMA; MALE; MEAN CORPUSCULAR VOLUME; MOUSE; NONHUMAN; PLASMA; PRIORITY JOURNAL; UPREGULATION; WESTERN BLOTTING; ANIMAL; ANOXIA; BLOOD; C57BL MOUSE; GENETICS; HUMAN; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOLUBILITY; TUMOR CELL LINE;

MUS;

ADAM PROTEINS; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANOXIA; BLOTTING, WESTERN; CELL LINE, TUMOR; CHRONIC DISEASE; GENE EXPRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HMGB1 PROTEIN; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LACTOYLGLUTATHIONE LYASE; LUNG; MALE; MEMBRANE PROTEINS; MICE, INBRED C57BL; PROTEIN ISOFORMS; RECEPTORS, IMMUNOLOGIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOLUBILITY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84923169326     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.02.003     Document Type: Article

References (61)

1. Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992, 267(21):14998-15004.
2. Kumano-Kuramochi M., Ohnishi-Kameyama M., Xie Q., Niimi S., Kubota F., Komba S., Machida S. Minimum stable structure of the receptor for advanced glycation end product possesses multi ligand binding ability. Biochem. Biophys. Res. Commun. 2009, 386(1):130-134.
3. Sparvero L.J., Asafu-Adjei D., Kang R., Tang D., Amin N., Im J., Rutledge R., Lin B., Amoscato A.A., Zeh H.J., et al. RAGE (Receptor for Advanced Glycation Endproducts), RAGE ligands, and their role in cancer and inflammation. J. Transl. Med. 2009, 7:17.
4. Alexiou P., Chatzopoulou M., Pegklidou K., Demopoulos V.J. RAGE: a multi-ligand receptor unveiling novel insights in health and disease. Curr. Med. Chem. 2010, 17(21):2232-2252.
5. Clynes R., Moser B., Yan S.F., Ramasamy R., Herold K., Schmidt A.M. Receptor for AGE (RAGE): weaving tangled webs within the inflammatory response. Curr. Mol. Med. 2007, 7(8):743-751.
6. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., Reiss K., Saftig P., Bianchi M.E. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. 2008, 22(10):3716-3727.
7. Hudson B.I., Carter A.M., Harja E., Kalea A.Z., Arriero M., Yang H., Grant P.J., Schmidt A.M. Identification, classification, and expression of RAGE gene splice variants. FASEB J. 2008, 22(5):1572-1580.
8. Kalea A.Z., Reiniger N., Yang H., Arriero M., Schmidt A.M., Hudson B.I. Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene. FASEB J. 2009, 23(6):1766-1774.
9. Yamakawa N., Uchida T., Matthay M.A., Makita K. Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2011, 300(4):L516-L525.
10. Demling N., Ehrhardt C., Kasper M., Laue M., Knels L., Rieber E.P. Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res. 2006, 323(3):475-488.
11. Mauri T., Masson S., Pradella A., Bellani G., Coppadoro A., Bombino M., Valentino S., Patroniti N., Mantovani A., Pesenti A., et al. Elevated plasma and alveolar levels of soluble receptor for advanced glycation end products are associated with severity of lung dysfunction in ARDS patients. Tohoku J. Exp. Med. 2010, 222(2):105-112.
12. Cohen M.J., Carles M., Brohi K., Calfee C.S., Rahn P., Call M.S., Chesebro B.B., West M.A., Pittet J.F. Early release of soluble receptor for advanced glycation end products after severe trauma in humans. J. Trauma 2010, 68(6):1273-1278.
13. Jing R., Cui M., Wang J., Wang H. Receptor for advanced glycation end products (RAGE) soluble form (sRAGE): a new biomarker for lung cancer. Neoplasma 2010, 57(1):55-61.
14. Smith D.J., Yerkovich S.T., Towers M.A., Carroll M.L., Thomas R., Upham J.W. Reduced soluble receptor for advanced glycation end-products in COPD. Eur. Respir. J. 2011, 37(3):516-522.
15. Gopal P., Rutten E.P., Dentener M.A., Wouters E.F., Reynaert N.L. Decreased plasma sRAGE levels in COPD: influence of oxygen therapy. Eur. J. Clin. Investig. 2012, 42(8):807-814.
16. Miniati M., Monti S., Basta G., Cocci F., Fornai E., Bottai M. Soluble receptor for advanced glycation end products in COPD: relationship with emphysema and chronic cor pulmonale: a case-control study. Respir. Res. 2011, 12:37.
17. Stogsdill J.A., Stogsdill M.P., Porter J.L., Hancock J.M., Robinson A.B., Reynolds P.R. Embryonic overexpression of receptors for advanced glycation end-products by alveolar epithelium induces an imbalance between proliferation and apoptosis. Am. J. Respir. Cell Mol. Biol. 2012, 47(1):60-66.
18. Stogsdill M.P., Stogsdill J.A., Bodine B.G., Fredrickson A.C., Sefcik T.L., Wood T.T., Kasteler S.D., Reynolds P.R. Conditional overexpression of receptors for advanced glycation end-products in the adult murine lung causes airspace enlargement and induces inflammation. Am. J. Respir. Cell Mol. Biol. 2013, 49(1):128-134.
19. Reynolds P.R., Cosio M.G., Hoidal J.R. Cigarette smoke-induced Egr-1 upregulates proinflammatory cytokines in pulmonary epithelial cells. Am. J. Respir. Cell Mol. Biol. 2006, 35(3):314-319.
20. Morbini P., Villa C., Campo I., Zorzetto M., Inghilleri S., Luisetti M. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease?. Mod. Pathol. 2006, 19(11):1437-1445.
21. Wu L., Ma L., Nicholson L.F., Black P.N. Advanced glycation end products and its receptor (RAGE) are increased in patients with COPD. Respir. Med. 2011, 105(3):329-336.
22. Sukkar M.B., Postma D.S. Receptor for advanced glycation end products and soluble receptor for advanced glycation end products: a balancing act in chronic obstructive pulmonary disease?. Am. J. Respir. Crit. Care Med. 2013, 188(8):893-894.
23. Uchida T., Shirasawa M., Ware L.B., Kojima K., Hata Y., Makita K., Mednick G., Matthay Z.A., Matthay M.A. Receptor for advanced glycation end-products is a marker of type I cell injury in acute lung injury. Am. J. Respir. Crit. Care Med. 2006, 173(9):1008-1015.
24. Su X., Lee J.W., Matthay Z.A., Mednick G., Uchida T., Fang X., Gupta N., Matthay M.A. Activation of the alpha7 nAChR reduces acid-induced acute lung injury in mice and rats. Am. J. Respir. Cell Mol. Biol. 2007, 37(2):186-192.
25. Reynolds P.R., Schmitt R.E., Kasteler S.D., Sturrock A., Sanders K., Bierhaus A., Nawroth P.P., Paine R., Hoidal J.R. Receptors for advanced glycation end-products targeting protect against hyperoxia-induced lung injury in mice. Am. J. Respir. Cell Mol. Biol. 2010, 42(5):545-551.
26. Gopal P., Reynaert N.L., Scheijen J.L., Schalkwijk C.G., Franssen F.M., Wouters E.F., Rutten E.P. Association of plasma sRAGE, but not esRAGE with lung function impairment in COPD. Respir. Res. 2014, 15(1):24.
27. Chang J.S., Wendt T., Qu W., Kong L., Zou Y.S., Schmidt A.M., Yan S.F. Oxygen deprivation triggers upregulation of early growth response-1 by the receptor for advanced glycation end products. Circ. Res. 2008, 102(8):905-913.
28. Sell D.R., Nemet I., Monnier V.M. Partial characterization of the molecular nature of collagen-linked fluorescence: role of diabetes and end-stage renal disease. Arch. Biochem. Biophys. 2010, 493(2):192-206.
29. Ramaekers C.H., van den Beucken T., Meng A., Kassam S., Thoms J., Bristow R.G., Wouters B.G. Hypoxia disrupts the Fanconi anemia pathway and sensitizes cells to chemotherapy through regulation of UBE2T. Radiother. Oncol. 2011, 101(1):190-197.
30. van den Borst B., Schols A.M., de Theije C., Boots A.W., Kohler S.E., Goossens G.H., Gosker H.R. Characterization of the inflammatory and metabolic profile of adipose tissue in a mouse model of chronic hypoxia. J. Appl. Physiol. (1985) 2013, 114(11):1619-1628.
31. Li Q.F., Wang X.R., Yang Y.W., Lin H. Hypoxia upregulates hypoxia inducible factor (HIF)-3alpha expression in lung epithelial cells: characterization and comparison with HIF-1alpha. Cell Res. 2006, 16(6):548-558.
32. Veikkola T., Alitalo K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 1999, 9(3):211-220.
33. Li X., Eriksson U. Novel VEGF family members: VEGF-B, VEGF-C and VEGF-D. Int. J. Biochem. Cell Biol. 2001, 33(4):421-426.
34. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U. S. A. 1998, 95(2):548-553.
35. Yamada Y., Nezu J., Shimane M., Hirata Y. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D. Genomics 1997, 42(3):483-488.
36. Pichiule P., Chavez J.C., Schmidt A.M., Vannucci S.J. Hypoxia-inducible factor-1 mediates neuronal expression of the receptor for advanced glycation end products following hypoxia/ischemia. J. Biol. Chem. 2007, 282(50):36330-36340.
37. Kang R., Hou W., Zhang Q., Chen R., Lee Y.J., Bartlett D.L., Lotze M.T., Tang D., Zeh H.J. RAGE is essential for oncogenic KRAS-mediated hypoxic signaling in pancreatic cancer. Cell Death Dis. 2014, 5:e1480.
38. Queisser M.A., Kouri F.M., Konigshoff M., Wygrecka M., Schubert U., Eickelberg O., Preissner K.T. Loss of RAGE in pulmonary fibrosis: molecular relations to functional changes in pulmonary cell types. Am. J. Respir. Cell Mol. Biol. 2008, 39(3):337-345.
39. Reynolds P.R., Kasteler S.D., Schmitt R.E., Hoidal J.R. Receptor for advanced glycation end-products signals through Ras during tobacco smoke-induced pulmonary inflammation. Am. J. Respir. Cell Mol. Biol. 2011, 45(2):411-418.
40. Raucci A., Cugusi S., Antonelli A., Barabino S.M., Monti L., Bierhaus A., Reiss K., Saftig P., Bianchi M.E. A soluble form of the receptor for advanced glycation end products (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10). FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2008, 22(10):3716-3727.
41. Metz V.V., Kojro E., Rat D., Postina R. Induction of RAGE shedding by activation of G protein-coupled receptors. PLoS One 2012, 7(7):e41823.
42. Estrada K.D., Chesler N.C. Collagen-related gene and protein expression changes in the lung in response to chronic hypoxia. Biomech. Model. Mechanobiol. 2009, 8(4):263-272.
43. Zhang S.X., Miller J.J., Stolz D.B., Serpero L.D., Zhao W., Gozal D., Wang Y. Type I epithelial cells are the main target of whole-body hypoxic preconditioning in the lung. Am. J. Respir. Cell Mol. Biol. 2009, 40(3):332-339.
44. Sharma A.K., LaPar D.J., Stone M.L., Zhao Y., Kron I.L., Laubach V.E. Receptor for advanced glycation end products (RAGE) on iNKT cells mediates lung ischemia-reperfusion injury. Am. J. Transplant. 2013, 13(9):2255-2267.
45. Iannitti R.G., Casagrande A., De Luca A., Cunha C., Sorci G., Riuzzi F., Borghi M., Galosi C., Massi-Benedetti C., Oury T.D., et al. Hypoxia promotes danger-mediated inflammation via receptor for advanced glycation end products in cystic fibrosis. Am. J. Respir. Crit. Care Med. 2013, 188(11):1338-1350.
46. Andrassy M., Volz H.C., Igwe J.C., Funke B., Eichberger S.N., Kaya Z., Buss S., Autschbach F., Pleger S.T., Lukic I.K., et al. High-mobility group box-1 in ischemia-reperfusion injury of the heart. Circulation 2008, 117(25):3216-3226.
47. Bauer E.M., Shapiro R., Zheng H., Ahmad F., Ishizawar D., Comhair S.A., Erzurum S.C., Billiar T.R., Bauer P.M. High mobility group box 1 contributes to the pathogenesis of experimental pulmonary hypertension via activation of Toll-like receptor 4. Mol. Med. 2012, 18:1509-1518.
48. Brownlee M. Negative consequences of glycation. Metabolism 2000, 49(2 Suppl 1):9-13.
49. Diamanti-Kandarakis E., Piperi C., Korkolopoulou P., Kandaraki E., Levidou G., Papalois A., Patsouris E., Papavassiliou A.G. Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J. Mol. Med. (Berl.) 2007, 85(12):1413-1420.
50. Smit P.J., Guo W.A., Davidson B.A., Mullan B.A., Helinski J.D., Knight P.R. Dietary advanced glycation end-products, its pulmonary receptor, and high mobility group box 1 in aspiration lung injury. J. Surg. Res. 2014, 191(1):214-223.
51. Bartling B., Fuchs C., Somoza V., Niemann B., Silber R.E., Simm A. Lung level of HMBG1 is elevated in response to advanced glycation end product-enriched food in vivo. Mol. Nutr. Food Res. 2007, 51(4):479-487.
52. Anderson M.M., Heinecke J.W. Production of N(epsilon)-(carboxymethyl)lysine is impaired in mice deficient in NADPH oxidase: a role for phagocyte-derived oxidants in the formation of advanced glycation end products during inflammation. Diabetes 2003, 52(8):2137-2143.
53. Miyata T., van Ypersele de Strihou C., Kurokawa K., Baynes J.W. Alterations in nonenzymatic biochemistry in uremia: origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 1999, 55:389-399. 2.
54. Quintero M., Gonzalez-Martin M.D., Vega-Agapito V., Gonzalez C., Obeso A., Farre R., Agapito T., Yubero S. The effects of intermittent hypoxia on redox status, NFkappaB activation, and plasma lipid levels are dependent on the lowest oxygen saturation. Free Radic. Biol. Med. 2013, 65:1143-1154.
55. Bucciarelli L.G., Kaneko M., Ananthakrishnan R., Harja E., Lee L.K., Hwang Y.C., Lerner S., Bakr S., Li Q., Lu Y., et al. Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury. Circulation 2006, 113(9):1226-1234.
56. Aleshin A., Ananthakrishnan R., Li Q., Rosario R., Lu Y., Qu W., Song F., Bakr S., Szabolcs M., D'Agati V., et al. RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model. Am. J. Physiol. Heart Circ. Physiol. 2008, 294(4):H1823-H1832.
57. Yan S.F., Ramasamy R., Schmidt A.M. The receptor for advanced glycation endproducts (RAGE) and cardiovascular disease. Expert Rev. Mol. Med. 2009, 11:e9.
58. Monnier V.M., Kohn R.R., Cerami A. Accelerated age-related browning of human collagen in diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 1984, 81(2):583-587.
59. Chang J.C., Ulrich P.C., Bucala R., Cerami A. Detection of an advanced glycosylation product bound to protein in situ. J. Biol. Chem. 1985, 260:7970-7974.
60. Moore S., Stein W.H. A modified ninydrin reagent for the photometric determination of amino acids and related compounds. J. Biol. Chem. 1954, 211:907-913.
61. Fan X., Sell D.R., Zhang J., Nemet I., Theves M., et al. Anaerobic vs aerobic pathways of carbonyl and oxidant stress in human lens and skin during aging and in diabetes: a comparative analysis. Free Radic. Biol. Med. 2010, 49:847-856.